Company Overview of Galena Biopharma, Inc.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company’s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical ...
4640 SW Macadam Avenue
Portland, OR 97239
Founded in 2003
Key Executives for Galena Biopharma, Inc.
Chief Executive Officer
Total Annual Compensation: $490.0K
Chief Financial Officer
Total Annual Compensation: $236.0K
Compensation as of Fiscal Year 2013.
Galena Biopharma, Inc. Key Developments
Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management
Jan 20 15
Galena Biopharma, Inc. announced it has hired Joseph Lasaga as Vice President, Business Development and Alliance Management, reporting to the President and CEO. Mr. Joseph Lasaga has more than 17 years of experience in the biotechnology and pharmaceutical industry in the areas of research and development, business development, alliance management and product strategy. Prior to joining Galena, Mr. Lasaga spent four years at Nektar Therapeutics, most recently as Senior Director, Business Development.
Galena Biopharma Provides Revenue Guidance for the Year 2014 and for the Year 2015
Jan 8 15
Galena Biopharma provided revenue guidance for the year 2014 and for the year 2015. For the year 2014, revenue in line with expectations and an outlook for 2015 that falls short of the consensus in an update of milestones expected for this year. The biopharmaceutical company expects 2014 revenue in the middle of its range of $8 million to $10 million after having its best quarter to date for sales in fourth quarter.
For 2015, the company expects revenue of $15 million to $18 million and expects its Abstral sublingual tablets for cancer pain to become accretive this year.
Galena Biopharma, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:00 PM
Jan 5 15
Galena Biopharma, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:00 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Mark W. Schwartz, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|